Q3 2026 Microbix Biosystems Inc Earnings Call Transcript
Key Points
- Microbix Biosystems Inc (MBXBF) reported solid year-over-year revenue growth of 17% in Q3 fiscal 2026, with antigen sales up 20% and CAPS sales up 13%.
- Gross margins improved significantly to 54% in Q3, up from 41% in the prior year, driven by better product mix and manufacturing efficiencies.
- The company is making strong progress on its Kinlytic therapeutic program, with major breakthroughs in drug substance process development that have increased yields and will improve margins.
- Microbix Biosystems Inc (MBXBF) is seeing growing B2C sales to end-user clinical labs, which increased 35% quarter-over-quarter and are becoming a more significant, recurring revenue stream.
- The company maintains a strong cash position of CAD7.2 million and is actively buying back shares, repurchasing 2.3 million shares year-to-date.
- Microbix Biosystems Inc (MBXBF) continues to report net losses, with a controlled net loss in Q3, indicating the company has not yet reached its break-even point.
- The company's revenue recovery is still below its goal of at least 20% year-over-year growth, and it remains dependent on a few large clients, which poses concentration risk.
- China sales, which had previously been a significant revenue source, have not fully recovered and are expected to remain below historical highs, with a return to only CAD2-3 million per year projected.
- The timeline for formalizing agreements with major international diagnostics companies is uncertain and largely controlled by clients, potentially delaying revenue growth.
- Government procurement for the VTM product line remains a frustration, with 95% of sales coming from outside Canada, limiting domestic market opportunities.
Good morning, everyone. Thanks for joining us today. We have a webinar with Microbix who just reported their Q3 results this morning.
Good results showing progress in the business. With me today, I have Cameron Groome, CEO; Jim Currie, CFO; and Ken Hughes, COO. I don't believe that we'll be working off a presentation, but this session will contain forward-looking statements. If you'd like to know more about those, you can find them on the company's presentation on their website. And the format today is going to be a quick overview of the quarter and some other key items. And then we're going to get into Q&A.
So if anyone has a question, feel free to enter that in the Q&A box at the bottom of your screen. And with that all out of the way, congrats, gentlemen.
Well, thank you.Thank you very much, Deborah appreciate it And Cameron, I think I'll turn the mic over to you.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
